Frank I. Lin, M.D.

Lasker Clinical Research Scholar

Molecular Imaging Program

NCI/CCR

Building 10, Room B3B69F
Bethesda, MD 20892-1088

301-496-7776

frank.lin2@nih.gov

Research Topics

The vision of the Targeted Radionuclide Therapy Section is to accelerate the development and clinical translation of radionuclide therapy as a treatment modality for cancer. Dr. Lin is interested in and investigates a number of different radionuclides in both clinical and pre-clinical settings, but is particularly interested in the application of alpha particle and Auger electron-emitting agents. In addition to agent development and research, Dr. Lin is also involved in the promotion and advancement of the field of radionuclide therapy, including educational pursuits such as the training of future medical practitioners of this promising form of therapy.

 

Biography

Originally born in Taiwan, Dr. Lin immigrated with his family to the U.S. at a very young age and grew up in California. Dr. Lin's educational and professional pursuits has since taken him to many different parts of the United States. He completed his undergraduate work in biological sciences at Stanford University and has a Masters degree in medical informatics from the University of Utah. He went to medical school at the Medical College of Wisconsin and did his internal medicine and nuclear medicine residencies at Kaiser Permanente San Francisco and the University of California, Davis, respectively. After re-joining Stanford University for a PET/CT fellowship, Dr. Lin has worked at the NCI for the past 6 years in the Cancer Imaging Program in the Division of Cancer Treatment and Diagnosis. He was selected as a Lasker Clinical Research Scholar in 2016 and made the transition to intramural NCI as head of the newly created Targeted Radionuclide Therapy Section housed within the Molecular Imaging Program headed by Dr. Peter Choyke.

Selected Publications

  1. Huang EP, Lin FI, Shankar LK. Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design. Acad Radiol. 2017;24(8):1036-1049.

  2. Lin FI, Huang EP, Shankar LK. Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment. Acad Radiol. 2017;24(8):1027-1035.

  3. Janssen I, Chen CC, Zhuang Z, Millo CM, Wolf KI, Ling A, Lin FI, Adams KT, Herscovitch P, Feelders RA, Fojo AT, Taieb D, Kebebew E, Pacak K. Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. J Nucl Med. 2017;58(8):1236-1242.

  4. Lin FI, Gonzalez EM, Kummar S, Do K, Shih J, Adler S, Kurdziel KA, Ton A, Turkbey B, Jacobs PM, Bhattacharyya S, Chen AP, Collins JM, Doroshow JH, Choyke PL, Lindenberg ML. Utility of <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy. Eur J Nucl Med Mol Imaging. 2017;44(3):500-508.

  5. Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, Adams KT, Wolf KI, Herscovitch P, Fojo AT, Buchmann I, Kebebew E, Pacak K. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43(10):1784-91.


This page was last updated on June 16th, 2017